PCRX vs. SUPN, AGIO, ADCT, AVIR, NKTR, MCRB, CORT, ALKS, PRGO, and SYRE
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Supernus Pharmaceuticals (SUPN), Agios Pharmaceuticals (AGIO), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), Nektar Therapeutics (NKTR), Seres Therapeutics (MCRB), Corcept Therapeutics (CORT), Alkermes (ALKS), Perrigo (PRGO), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
Pacira BioSciences received 339 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences has a net margin of 10.34% compared to Supernus Pharmaceuticals' net margin of -2.60%. Pacira BioSciences' return on equity of 12.98% beat Supernus Pharmaceuticals' return on equity.
99.7% of Pacira BioSciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Pacira BioSciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Pacira BioSciences currently has a consensus target price of $47.40, indicating a potential upside of 53.80%. Supernus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 40.89%. Given Pacira BioSciences' higher possible upside, equities analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
In the previous week, Pacira BioSciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 4 mentions for Pacira BioSciences and 2 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.93 beat Supernus Pharmaceuticals' score of 0.34 indicating that Pacira BioSciences is being referred to more favorably in the media.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
